Liu Miao, Lu Jing, Chen Yujuan, Zhang Dongmei, Huang Wei, Shi Mengqi, Zhang Yibin, Wu Tong, Chen Zhuming, Wu Lei, Chen Xinzhi, Wang Jian
College of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, China.
The First Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, China.
Evid Based Complement Alternat Med. 2023 Feb 8;2023:5301024. doi: 10.1155/2023/5301024. eCollection 2023.
The herbal pairing of Huangqi and Dangshen (HD) is traditional Chinese herbal medicine and has been widely used in China, especially to treat myasthenia gravis (MG). However, the mechanism of HD on MG is unclear. . This study aims to investigate HD's possible role in MG treatment. . The TCMSP database was used to identify the active chemicals and their targets. The GeneCards, DisGeNET, and OMIM databases were used to search for MG-related targets. The STRING database was employed in order to identify the common PPI network targets. We next utilised Cytoscape 3.8.2 for target identification and the DAVID database for gene ontology (GO) function analysis as well as Encyclopaedia of Genomes (KEGG) pathway enrichment analysis on the selected targets. The AutoDock Vina software was used to test the affinity of essential components with the hub gene before concluding that the primary targets were corrected through molecular docking. . 41 active compounds were screened from HD, and the number of putative-identified target genes screened from HD was 112. There were 21 target genes that overlapped with the targets of MG, which were postulated to be potential treatment targets. Through further analysis, the results showed that the active compounds from HD (such as 7-methoxy-2-methylisoflavone, quercetin, luteolin, Kaempferol, and isorhamnetin) may achieve the purpose of treating MG by acting on some core targets and related pathways (such as EGFR, FOS, ESR2, MYC, ESR1, CASP3, and IL-6). Molecular docking findings demonstrated that these active molecules have a near-perfect ability to attach to the primary targets. . Through network pharmacology, the findings in this study provide light on the coordinated action of several HD formula components, targets, and pathways. It provided a theoretical basis for further study of HD pharmacological action.
黄芪和党参药对（HD）是传统中药，在中国已被广泛应用，尤其用于治疗重症肌无力（MG）。然而，HD治疗MG的机制尚不清楚。本研究旨在探讨HD在MG治疗中的可能作用。利用中药系统药理学数据库与分析平台（TCMSP）数据库识别活性成分及其靶点。使用基因卡片（GeneCards）、疾病基因数据库（DisGeNET）和在线人类孟德尔遗传数据库（OMIM）搜索与MG相关的靶点。利用STRING数据库识别常见的蛋白质-蛋白质相互作用（PPI）网络靶点。接下来，我们使用Cytoscape 3.8.2进行靶点识别，并使用DAVID数据库对选定的靶点进行基因本体（GO）功能分析以及京都基因与基因组百科全书（KEGG）通路富集分析。在通过分子对接确定主要靶点之前，使用AutoDock Vina软件测试必需成分与枢纽基因的亲和力。从HD中筛选出41种活性化合物，从HD中筛选出的假定鉴定靶点基因数量为112个。有21个靶点基因与MG的靶点重叠，这些基因被假定为潜在的治疗靶点。通过进一步分析，结果表明HD中的活性化合物（如7-甲氧基-2-甲基异黄酮、槲皮素、木犀草素、山奈酚和异鼠李素）可能通过作用于一些核心靶点和相关通路（如表皮生长因子受体（EGFR）、原癌基因FOS、雌激素受体2（ESR2）、原癌基因MYC、雌激素受体1（ESR1）、半胱天冬酶3（CASP3）和白细胞介素-6（IL-6））来达到治疗MG的目的。分子对接结果表明，这些活性分子与主要靶点具有近乎完美的结合能力。通过网络药理学，本研究结果揭示了HD配方中几种成分、靶点和通路的协同作用。它为进一步研究HD的药理作用提供了理论依据。
